← Back to Search

Blood Product

Slow vs Standard Platelet Transfusion for Low Platelet Count

Phase 2

Recruiting

Led By Willy A Flegel, M.D.

Research Sponsored by National Institutes of Health Clinical Center (CC)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Thrombocytopenia

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3-years

Awards & highlights

Study Summary

This trial is testing whether transfusing platelets more slowly than the standard rate can be more effective for people with PTR. Blood will be drawn before and after transfusions to study the effects.

Who is the study for?

Adults aged 18-100 with very low platelet counts who need a transfusion and have platelet transfusion refractoriness (PTR), meaning standard transfusions don't increase their platelet count enough. They must understand the study and agree to participate. Excluded are those responsive to certain immune therapies, under 18, unable to consent, with autoimmune thrombocytopenia or pregnant women.Check my eligibility

What is being tested?

The trial is testing if giving platelets more slowly than usual can help people whose bodies don't respond well to normal transfusions. Participants will receive two types of transfusions: one over an hour (SHORT) and another over four hours (LONG). They'll be randomly assigned an order for these treatments.See study design

What are the potential side effects?

Potential side effects from the different rates of platelet transfusion aren't specified in detail but may include reactions similar to regular blood product transfusions such as fever, allergic reactions, or infection at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a low platelet count.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3-years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3-years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adusted platelet measurement area under the curve (AUC)

Secondary outcome measures

Impact on bleeding

Trial Design

2Treatment groups

Active Control

Group I: Group AActive Control2 Interventions

Group A: Long Transfusion followed by Short Transfusion in the first block

Group II: Group BActive Control2 Interventions

Group B: Short Transfusion followed by Long Transfusion in the first block

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institutes of Health Clinical Center (CC)Lead Sponsor

383 Previous Clinical Trials

880,972 Total Patients Enrolled

Willy A Flegel, M.D.Principal InvestigatorNational Institutes of Health Clinical Center (CC)

2 Previous Clinical Trials

163 Total Patients Enrolled

Media Library

Platelet Transfusion - LONG Platelet Transfusion (Blood Product) Clinical Trial Eligibility Overview. Trial Name: NCT03712618 — Phase 2

Platelet Transfusion Research Study Groups: Group A, Group B

Platelet Transfusion Clinical Trial 2023: Platelet Transfusion - LONG Platelet Transfusion Highlights & Side Effects. Trial Name: NCT03712618 — Phase 2

Platelet Transfusion - LONG Platelet Transfusion (Blood Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03712618 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is able to participate in this medical experiment?

"Patients with thrombocytopenia and aged between 18-100 are welcomed to participate in this medical trial. Up to 30 people may be accepted into the study."

Answered by AI

Does this medical trial have an upper limit for patient age?

"For this research project, only individuals aged 18 to 100 qualify for participation. In addition, there are 24 clinical trials specifically designed for minors and 103 trials catered towards seniors."

Answered by AI

Are there any open recruitment slots available for this clinical experiment?

"Clinicaltrials.gov shows that this research is presently recruiting patients, having been posted on June 10th 2019 and revised most recently November 1st 2022."

Answered by AI

Is there any danger posed to patients by Group B?

"The safety of Group B was assessed to be a 2 because, being in the Phase 2 stage, there is some existing data suggesting its security but not yet evidence for efficacy."

Answered by AI

What is the cap on patient enrollment for this clinical experiment?

"Affirmative. Evidence from clinicaltrials.gov implies that this medical study, initially published on June 10th 2019, is currently recruiting participants. 30 subjects are required to be enrolled across a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The SOLID Platelet Study

2019. "The SOLID Platelet Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03712618.

All > Thrombocytopenia